Vai al contenuto principale della pagina
Titolo: | Dyslipidemia / / Ragavendra R. Baliga, Christopher P. Cannon |
Pubblicazione: | Oxford ; ; New York, : Oxford University Press, 2012 |
Edizione: | 1st ed. |
Descrizione fisica: | 1 online resource (152 p.) |
Disciplina: | 616.3/997 |
616.3997 | |
Soggetto topico: | Lipids - Metabolism - Disorders - Treatment |
Atherosclerosis - Treatment | |
Coronary heart disease | |
Altri autori: | BaligaR. R CannonChristopher P |
Note generali: | Description based upon print version of record. |
Nota di bibliografia: | Includes bibliographical references and index. |
Nota di contenuto: | Cover; Contents; Contributors; 1 LDL Cholesterol; 2 HDL Cholesterol; 3 Non-HDL Cholesterol; 4 Use of High Sensitivity C-Reactive Protein for Risk Assessment; 5 Advanced Lipoprotein Testing: Assessment of Cardiovascular Risk and Therapy Beyond Standard Lipid Measurements; 6 Stratification of Dyslipidemic Risk; 7 Drugs for Treatment of Blood Lipoprotein Abnormalities; Index; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; Q; R; S; T; V; W; X; Z |
Sommario/riassunto: | Dyslipidemia affects almost half of American adults and is the most prevalent manageable risk factor for atherosclerosis. Lipid disorders often co-occur with other prevalent conditions such as diabetes and kidney disease; they are also often a concern with certain medication regimens (such as anti-retroviral and certain anti-psychotic agents). Proper treatment of dyslipidemia can reduce the risk of peripheral arterial disease, revascularization procedures, nonfatal myocardial infarction, stroke, and cardiac death. However, only 20% of adults meet the national guidelines for cholesterol control |
Titolo autorizzato: | Dyslipidemia |
ISBN: | 1-283-57735-6 |
9786613889805 | |
0-19-978037-4 | |
Formato: | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione: | Inglese |
Record Nr.: | 9910828909203321 |
Lo trovi qui: | Univ. Federico II |
Opac: | Controlla la disponibilità qui |